CD8A and cancer: Furthermore, Baljon et al. recently developed a nanoparticle vaccine platform for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists to enhance antigen-specific CD8+ T cell responses and improve the efficacy of immune checkpoint blockade in cancer immunotherapy (Fig. 3) [82].